LQDA · Liquidia Corp
United States · RS rating 17 · As of 2026-10-14
| Price | 33.94 USD |
|---|---|
| 1-day change | +26.6% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 3 / 4 / 87 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 42 / 31 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +246.7% |
| Sales growth Q/Q | +69.3% |
| Distance from 52-week high | +62.7% |
| Market cap (USD) | $3.3B |